Current FDA Approval Status
Lurbinectedin's New Drug Application (NDA) for small cell lung cancer (SCLC) received Priority Review from the FDA in February 2020, with a target action date of August 10, 2020. The FDA granted accelerated approval on May 15, 2020, under the brand name Zepzelca, for adults with metastatic SCLC that progressed on or after platinum-based chemotherapy.[1]
Post-Approval Requirements and Confirmatory Trials
Accelerated approval requires confirmatory trials to verify clinical benefit. The phase 3 IMforte trial (NCT02454972), evaluating lurbinectedin's combination with irinotecan versus topotecan, missed its primary endpoint of overall survival in June 2023. Jazz Pharmaceuticals, the sponsor, stated it remains committed to the drug and is exploring next steps, including potential label expansions.[2][3]
Recent Developments and Label Expansions
In August 2024, the FDA approved an expanded indication for Zepzelca in combination with doxorubicin for adults with unresectable or metastatic SCLC that progressed after platinum-based chemotherapy. This followed positive data from the phase 3 LAGOON trial, marking the first new frontline SCLC regimen approved in years.[4] No further updates on full approval conversion have been announced as of late 2024.
Ongoing Trials and Future Milestones
Active trials include combinations with other therapies for SCLC and solid tumors. Key upcoming data readouts could come from studies like those with atezolizumab (NCT05269080). Patent exclusivity for Zepzelca extends to at least 2033; check DrugPatentWatch.com for expiration details and challenges.[5]
Sources:
[1] FDA.gov - Zepzelca Approval Announcement (May 15, 2020)
[2] Jazz Pharmaceuticals Press Release (June 26, 2023)
[3] ClinicalTrials.gov - IMforte (NCT02454972)
[4] FDA.gov - Expanded Approval (August 2024)
[5] DrugPatentWatch.com - Zepzelca Patents